Limited Value of the Multi-Biomarker Disease Activity Assay Compared to the Routine Assessment of Patient Index Data 3 (RAPID3) Score in the Prognosis of Important Clinical Outcomes in Rheumatoid Arthritis: Comment on the Article by Fleischmann et a

scientific article published on 3 March 2017

Limited Value of the Multi-Biomarker Disease Activity Assay Compared to the Routine Assessment of Patient Index Data 3 (RAPID3) Score in the Prognosis of Important Clinical Outcomes in Rheumatoid Arthritis: Comment on the Article by Fleischmann et a is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/ART.40022
P698PubMed publication ID27992686

P50authorTheodore PincusQ64689192
P2093author name stringJoel A Block
Tuulikki Sokka
Yusuf Yazici
Martin J Bergman
P2860cites workAcute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity scoreQ24817087
RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categoriesQ33369498
A biopsychosocial model to complement a biomedical model: patient questionnaire data and socioeconomic status usually are more significant than laboratory tests and imaging studies in prognosis of rheumatoid arthritisQ33517262
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritisQ34315745
The need for a new medical model: a challenge for biomedicineQ34363431
Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activityQ36428250
Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or AdalimumabQ39824928
Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United StatesQ45226600
MDHAQ/RAPID3 to recognize improvement over 2 months in usual care of patients with osteoarthritis, systemic lupus erythematosus, spondyloarthropathy, and gout, as well as rheumatoid arthritisQ46641202
P433issue4
P921main subjectrheumatoid arthritisQ187255
biomarkerQ864574
P304page(s)866-867
P577publication date2017-03-03
P1433published inArthritis & RheumatologyQ4797636
P1476titleLimited Value of the Multi-Biomarker Disease Activity Assay Compared to the Routine Assessment of Patient Index Data 3 (RAPID3) Score in the Prognosis of Important Clinical Outcomes in Rheumatoid Arthritis: Comment on the Article by Fleischmann et a
P478volume69

Search more.